Sight Sciences, Inc., a venture-backed, commercial-stage ophthalmic medical device company announced today that it has received Health Canada approval for the TRAB360 Trabeculotomy System. The TRAB360 is indicated in Canada for the microcatheterization of Schlemm’s canal and cutting of trabecular meshwork to lower intraocular pressure in patients with primary open angle glaucoma.